RESEARCH ARTICLE

Digital health device measured sleep duration and ideal cardiovascular health: an observational study

Jane A. Leopold1* and Elliott M. Antman1,2

Abstract
Background: Studies relying on self-reported sleep data suggest that there is an association between short and long sleep duration and less than ideal cardiovascular health. Evidence regarding the feasibility of using digital health devices to measure sleep duration and assess its relationship to ideal cardiovascular health are lacking. The objective of the present study was to utilize digital health devices to record sleep duration and examine the relationship between sleep duration and ideal cardiovascular health.

Methods: A total of 307 participants transmitted sleep duration data from digital health devices and answered the Life’s Simple 7 survey instrument to assess ideal cardiovascular health. Sleep duration was defined as adequate (7 to < 9 h per night) or non-adequate (< 7 h and ≥ 9 h).

Results: We identified three sleep-cardiovascular health phenogroups: resilient (non-adequate sleep and ideal cardiovascular health), uncoupled (adequate sleep and non-ideal cardiovascular health) or concordant (sleep and cardiovascular health metrics were aligned). Participants in the resilient phenogroup (n = 83) had better cardiovascular health factor profiles (blood pressure, blood glucose and cholesterol levels) and behaviors (healthy weight, diet, exercise, smoking) than participants in the concordant (n = 171) and uncoupled (n = 53) phenogroups. This was associated with higher Life’s Simple 7 Health Scores in the resilient phenogroup compared to the concordant and uncoupled phenogroups (7.8 ± 0.8 vs. 7.0 ± 1.4 vs. 5.6 ± 0.7, P < 0.01).

Conclusion: This study identified three distinct sleep-ideal cardiovascular health phenogroups and highlights the advantage of incorporating sleep assessments into studies of cardiovascular health. Future studies should focus on the relationship between sleep-cardiovascular phenogroups and clinical outcomes.

Clinical Trial Registration Clinicaltrials.gov NCT02958098. Date of registration: November 11, 2016.

Keywords: Sleep, Phenogroups, Digital health devices, Surveys, Ideal cardiovascular health

Background
Accumulating evidence demonstrates the relationship between sleep and cardiovascular disease. Recent estimates from the United States indicate that only 65.2% of individuals self-report a sleep duration of 7 to < 9 h per night as recommended by the American Academy of Sleep Medicine [1, 2]. The relationship between sleep duration and cardiovascular disease has been described as a U-shaped association [3]. Studies have found that individuals that self-report very short (< 6 h) or long (≥ 9 h) sleep duration have an increased incidence and prevalence of hypertension, coronary heart disease, and cerebrovascular disease [4–10]. The relationship...
between short sleep duration and cardiovascular diseases has been attributed to surges in blood pressure, sympathoexcitatory effects, cardiac conduction system abnormalities, vascular dysfunction, impaired glucose homeostasis, inflammation, and circadian rhythm disruption [4]. In contrast, the mechanisms underlying the adverse effects of long sleep duration on the development of cardiovascular diseases are less well characterized. It has been suggested that long sleep duration is a marker for other health factors and behaviors, such as metabolic syndrome, tobacco use, or low levels of physical activity [4].

In 2010, the American Heart Association developed the Life's Simple 7 survey tool to assess ideal cardiovascular health [11]. The survey instrument defines ideal cardiovascular health as a composite of 7 modifiable health factors and behaviors, including healthy weight, blood pressure, cholesterol, and blood glucose as well as a healthy diet, absence of tobacco use, and moderate and vigorous exercise [11, 12]. The overall Life’s Simple 7 Health Score has been linked to cardiovascular disease with lower scores associated with an increased incidence of adverse cardiovascular outcomes: for each 1 unit decrease in the score, there is an associated 12% increased risk of adverse cardiovascular events [13–15]. Similarly, individuals that have ideal scores for fewer than five of the 7 categories evaluated by the Life’s Simple 7 survey have an increased risk for developing cardiovascular disease [16, 17].

Recently, investigators have begun to examine the relationship between sleep duration and ideal cardiovascular health. One study that included only women found that women who self-reported adequate sleep duration, defined as ≥ 7 h per night, were more likely to have ideal scores in five or more of Life's Simple 7 health factors and habits categories [18]. Another cross-sectional study performed using National Health and Nutrition Examination Survey (NHANES) data found that individuals who self-reported a very short (<6 h) or a very long (≥9 h) sleep duration had decreased odds of ideal cardiovascular health [19]. In the current study, we hypothesized that digital health devices would provide an objective measurement of sleep duration and allow us to evaluate the relationship between sleep duration and ideal cardiovascular health.

### Methods

**Study cohort**

The My Research Legacy study was a direct-to-participant study sponsored by the American Heart Association (NCT 02958098) and open for enrollment between November 2016 and October 2018 [20]. The study was approved by the Advarra Institutional Review Board (#31995) and all participants signed informed consent. The study was open to participants in the United States who were ≥ 18 years old and had internet access. Participants self-reported baseline demographics, their history of cardiovascular disease, and completed the Life's Simple 7 survey instrument [11, 12]. A subset of participants were provided with a Fitbit Charge 2 device, which incorporates sleep staging [21], or registered their own digital health device with the study. Participants that had digital scales linked these to their digital health device. Participant digital health data was uploaded to Validic (Validic Inc., Durham, NC). Deidentified data were parsed into sleep, weight, fitness, and routine categories via the Validic API, and transmitted to secure servers managed by The Broad Institute (Cambridge, MA) and REAN Cloud LLC (Herndon, VA).

**Sleep duration and ideal cardiovascular health**

Sleep duration was determined by obtaining an average of total sleep hours recorded from 7 consecutive days to account for daily and workday-weekend variations. When 7 consecutive days were not available, an average of the consecutive days available was used. Adequate sleep duration was defined as ≥ 7 to < 9 h per night based on recommendations from the American Academy of Sleep Medicine and non-adequate sleep duration was defined as < 7 h and ≥ 9 h per night [1]. Light, deep, and rapid eye movement (REM) sleep stages were determined using post-processed heart rate signals by proprietary algorithms specific to the device manufacturer. Sleep stage duration was obtained by averaging data obtained over 7 days.

Ideal cardiovascular health was assessed using the Life’s Simple 7 survey tool. Participants answered questions related to health factors (weight, blood pressure, cholesterol and blood glucose levels) as well health behaviors (diet, exercise, smoking). The Life’s Simple 7 survey provides an assessment of ideal cardiovascular health by assigning participants a score of 0, 1, or 2 (poor, intermediate, and ideal) for 7 cardiovascular health and habit categories according to criteria defined by a panel of experts. A final Health Score, which takes into consideration medication use to manage cardiovascular risk factors is calculated and can range between 0 (poor) and 10 (ideal) [11, 12]. Ideal cardiovascular health was defined by an overall Health Score of ≥7.0 or by meeting ideal criteria for a minimum of 5 categories [22, 23].

**Statistical analysis**

Sample size to assess sleep data was calculated based on a reported prevalence of non-adequate sleep ranging from 26.3% to 46.3% in the general population [24]. We assumed that our study population would have a similar prevalence of non-adequate sleep. To achieve 90% power
with an alpha = 0.05, the minimum sample size required was 254 participants.

Data are presented as mean ± SD and \( P \) values < 0.05 were considered significant. Comparisons between continuous variables were analyzed using t-tests or one-way ANOVA as applicable. Post-hoc pairwise comparisons between groups was performed using Bonferroni correction testing. Comparisons between categorical variables were analyzed using the chi-square test or Fisher’s exact test. Nonparametric testing was done using the Wilcoxon-rank sum test or Kruskal–Wallis test. Post-hoc pairwise comparisons between groups was performed using Dunn’s test. Data were analyzed using Stata 15/SE 15.1 (StataCorp LLC, College Station, TX) and Prism 9.0 (GraphPad, San Diego, CA).

**Results**

A total of 342 participants contributed sleep data from their registered digital health devices. From this group, 35 participants were excluded due to incomplete Life’s Simple 7 data or incomplete recorded sleep data leaving a final sample size of 307 participants (Fig. 1). There were 146 participants who were categorized as having adequate sleep duration (\( \geq 7 \) to < 9 h/night) and slept an average of 7.6 ± 0.5 h/night. The remaining 161 participants who were categorized as having non-adequate sleep (< 7 \( [n = 144] \) and \( \geq 9 \ [n = 17] \) hours/night) slept

![Study Flowchart](image)

![Relationship between sleep and cardiovascular health score](image)
| Demographics                                                                 | Resilient (n = 83) | Concordant (n = 171) | Uncoupled (n = 53) | P value |
|------------------------------------------------------------------------------|--------------------|----------------------|--------------------|---------|
| Age (yrs)                      | 41.2 ± 13.7        | 43.2 ± 13.2          | 47.1 ± 10.8        | < 0.04  |
| Female (%)                     | 88.0               | 77.8                 | 79.3               | 0.15    |
| Race and ethnicity (no.)       |                    |                      |                    | 0.87    |
| Asian                          | 3                  | 6                    | 0                  |         |
| Black                          | 3                  | 6                    | 1                  |         |
| Hispanic                       | 3                  | 9                    | 2                  |         |
| White                          | 71                 | 146                  | 47                 |         |
| Other                          | 3                  | 4                    | 3                  |         |
| Region (no.)                   |                    |                      |                    | 0.96    |
| Northeast                      | 14                 | 26                   | 11                 |         |
| South                          | 31                 | 66                   | 18                 |         |
| Midwest                        | 24                 | 47                   | 14                 |         |
| West                           | 14                 | 33                   | 10                 |         |
| Diagnosed with cardiovascular disease (%)                                 | 41.0               | 36.8                 | 45.3               | 0.52    |
| Diabetes mellitus (%)          | 0                  | 5.8                  | 15.1               | < 0.01  |
| Hypertension (%)               | 38.6               | 46.2                 | 60.4               | < 0.05  |
| Hypercholesterolemia (%)       | 38.6               | 49.7                 | 75.5               | < 0.01  |
| Medications (%)                |                    |                      |                    |         |
| Diabetes mellitus (%)          | 0                  | 4.1                  | 15.1               | < 0.01  |
| Hypertension (%)               | 108                | 25.1                 | 45.3               | < 0.01  |
| Hypercholesterolemia (%)       | 108                | 18.7                 | 32.1               | < 0.01  |
| Smoking status (%)             |                    |                      |                    | 0.07    |
| Current                        | 0                  | 1.2                  | 1.9                |         |
| Quit < 12 months               | 1.2                | 2.3                  | 5.7                |         |
| Quit ≥ 12 months               | 21.7               | 23.4                 | 39.6               |         |
| Never                          | 77.1               | 73.1                 | 52.8               |         |
| Clinical data                  |                    |                      |                    |         |
| Weight (kg)                    | 71.2 ± 13.8        | 80.4 ± 20.1          | 93.2 ± 19.0        | < 0.01  |
| BMI (kg/m²)                    | 25.2 ± 4.2         | 28.4 ± 7.1           | 33.0 ± 6.0         | < 0.01  |
| Systolic blood pressure (mmHg) | 114.1 ± 10.3       | 118.3 ± 13.4         | 117.9 ± 10.9       | < 0.04  |
| Diastolic blood pressure (mmHg)| 71.4 ± 7.3         | 73.0 ± 8.5           | 73.1 ± 7.5         | 0.28    |
| Total cholesterol (mg/dL)       | 183.1 ± 29.6       | 188.0 ± 31.4         | 194.2 ± 27.8       | 0.11    |
| Blood glucose (mg/dL)          | 94.6 ± 8.0         | 98.1 ± 18.1          | 101.8 ± 15.7       | < 0.03  |
| Diet                           |                    |                      |                    |         |
| Vegetables/day (cups)          | 2.2 ± 1.5          | 1.8 ± 1.3            | 1.5 ± 0.9          | < 0.01  |
| Fruit/day (cups)               | 1.6 ± 1.1          | 1.3 ± 1.0            | 1.2 ± 0.8          | < 0.03  |
| Fish (servings/week)           | 1.0 ± 1.2          | 0.9 ± 1.0            | 1.0 ± 1.2          | 0.66    |
| Whole grains (servings/day)     | 1.8 ± 1.4          | 1.8 ± 1.3            | 1.2 ± 0.8          | < 0.01  |
| Sugar-sweetened beverages (servings/week) | 1.7 ± 2.9 | 1.6 ± 2.4 | 2.1 ± 2.8 | 0.56    |
| Avoid prepackaged foods (%)    | 54.2               | 50.9                 | 39.6               | 0.23    |
| Avoid eating out (%)           | 39.8               | 36.3                 | 26.4               | 0.27    |
| Avoid salt at home (%)         | 61.5               | 60.2                 | 54.7               | 0.72    |
| Exercise                       |                    |                      |                    |         |
| Moderate exercise (min/week)   | 198.7 ± 168.3      | 218.9 ± 223.9        | 172.4 ± 161.0      | 0.32    |
| Vigorous exercise (min/week)   | 77.5 ± 115.6       | 98.2 ± 127.1         | 34.8 ± 64.1        | < 0.01  |
| LS7 score                      |                    |                      |                    | 0.82    |
| Smoking score (%)              | 0                  | 1.2                  | 1.9                |         |
an average of 6.4±1.2 h/night. A subset of participants (n = 131 with non-adequate sleep and n = 84 with adequate sleep) provided sleep stage data. Compared to participants with non-adequate sleep, individuals with adequate sleep spent more time in deep sleep (58.1±17.2 vs. 69.1±16.8 min/night, P < 0.01) and REM sleep (75.6±22.6 vs. 97.0±20.6 min/night, P < 0.01). Participants with non-adequate sleep were less likely to have ideal cardiovascular health when assessed by having an ideal score in 5 or more Life’s Simple 7 health factors and behaviors categories (21.7% vs. 37.0%, P < 0.01) or by the Life’s Simple 7 Health Score (6.8±1.3 vs. 7.2±1.4, P < 0.01).

Among our participants, three phenogroups that describe the sleep-ideal cardiovascular health relationship emerged: resilient, concordant, and uncoupled. The resilient phenogroup (n = 83) was characterized by ideal cardiovascular health, but non-adequate sleep while the uncoupled phenogroup (n = 53) had non-ideal cardiovascular health, but adequate sleep. The concordant phenogroup (n = 171) had alignment of cardiovascular health and sleep duration (either non-ideal cardiovascular health and non-adequate sleep or ideal cardiovascular health and adequate sleep) (Fig. 2).

Participants in the resilient phenogroup were younger (41.2±13.7 vs. 43.2±13.2 vs. 47.1±10.8 yrs, P < 0.04) than those in the concordant and uncoupled phenogroups and were less likely to have a history of diabetes mellitus (P < 0.01), hypertension (P < 0.05), or hypercholesterolemia (P < 0.01) or to take medications for...
these cardiovascular disease risk factors (all $P<0.01$) (Table 1). Participants in the resilient group also had significantly lower weight and body mass index ($25.2 \pm 4.2$ vs. $28.4 \pm 7.1$ vs. $33.0 \pm 6.0$ kg/m$^2$, $P<0.01$) than the concordant and uncoupled phenogroups as well as lower systolic blood pressures ($P<0.04$) and blood glucose levels ($P<0.03$) (Table 1). There were also differences between the groups with respect to other modifiable cardiovascular health behaviors, such as diet and exercise. Individuals in the resilient phenogroup consumed more daily servings of vegetables ($P<0.01$), fruits ($P<0.03$), and whole grains ($P<0.01$) than individuals in the uncoupled phenogroup. While there was no difference between the phenogroups with respect to minutes of moderate exercise per week, both the resilient and concordant phenogroups self-reported more minutes of vigorous exercise per week than individuals in the uncoupled phenogroup ($76.5 \pm 115.6$ vs. $98.2 \pm 127.1$ vs. $34.8 \pm 64.1$ min/week, $P<0.01$). Participants in the resilient phenogroup were more likely to have ideal scores in 5 or more Life’s Simple 7 health factors and behaviors (Fig. 3). Participants in the resilient phenogroup also had better Life’s Simple 7 Health Scores than participants in the concordant or uncoupled phenogroups ($7.8 \pm 0.8$ vs. $7.0 \pm 1.4$ vs. $5.6 \pm 0.7$, $P<0.01$)(Fig. 4). We next sought to explore the concordant phenogroup in more detail as this group was comprised of participants who had adequate sleep and ideal cardiovascular health and were considered to have a healthy phenotype ($n=104$) as well as those individuals with inadequate sleep and non-ideal cardiovascular health who were considered to have an unhealthy phenotype ($n=67$). Those...
individuals with a healthy phenotype were younger (40.3 ± 13.5 vs. 47.6 ± 11.4 yrs, \( P < 0.01 \)), less likely to have hypertension (34.6 vs. 64.2\%, \( P < 0.01 \)), diabetes mellitus (1.9 vs. 11.9\%, \( P < 0.01 \)), or hypercholesterolemia (35.6 vs. 71.6\%, \( P < 0.01 \)), and had a lower body mass index (25.9 ± 5.2 vs. 23.2 ± 7.9 kg/m\(^2\), \( P < 0.01 \)) than unhealthy individuals. Individuals in the healthy phenotype group also subscribed to a heart healthy diet with a greater intake of daily vegetables (2.1 ± 1.3 vs. 1.4 ± 1.0 cups/day, \( P < 0.01 \)), fruits (1.5 ± 1.0 vs. 1.0 ± 0.7 cups/day, \( P < 0.01 \)), servings of fish/week (1.0 ± 1.1 vs. 0.7 ± 0.8 servings/week, \( P < 0.05 \)), and fewer servings of sugar-sweetened beverages per week (1.1 ± 1.9 vs. 2.3 ± 3.0 cups/day, \( P < 0.01 \)). While there was no difference between the two groups with respect to weekly minutes of moderate exercise, the healthy group performed more weekly minutes of vigorous exercise (126.6 ± 134.8 vs. 54.2 ± 100.2 min, \( P < 0.01 \)) than the unhealthy group.

The digital health devices used to measure sleep duration also measured weight, activity, and daily step count. Weight measured by digital health devices and calculated body mass index remained lower in participants in the resilient phenogroup (\( n = 75 \)) as compared to the concordant (\( n = 145 \)) and uncoupled (\( n = 47 \)) phenogroups (both \( P < 0.01 \)) (Table 2). Participants in the resilient phenogroup also tended to underreport their weight while individuals in the uncoupled phenogroup overreported their weight on the Life’s Simple 7 survey as compared to what was measured by the digital health device (\( P < 0.01 \)). Using digital health device measured weight, there was a significant difference in the distribution of participants with poor, intermediate and ideal scores between the phenogroups (\( P < 0.01 \)). Interestingly, using digital health device measured exercise data, participants in the resilient phenogroup performed fewer minutes per week of moderate exercise than the other phenogroups (\( P < 0.04 \)), but similar minutes per week of vigorous exercise. This

### Table 2: Digital health device data

|                          | Resilient (\( n = 75 \)) | Concordant (\( n = 145 \)) | Uncoupled (\( n = 47 \)) | \( P \) value |
|--------------------------|--------------------------|-----------------------------|--------------------------|-------------|
| Weight (kg)\(^a,b,c\)    | 71.7 ± 14.6              | 81.7 ± 21.4                 | 92.4 ± 19.5              | <0.01       |
| Difference between self-reported and digital device measured (kg)\(^b,c\) | -1.1 ± 3.7              | -0.9 ± 4.1                  | 1.3 ± 5.5                 | <0.01       |
| BMI (kg/m\(^2\))\(^a,b,c\) | 25.5 ± 4.5              | 28.9 ± 7.5                  | 32.6 ± 6.3                | <0.01       |
| Difference between self-reported and digital device measured (kg/m\(^2\))\(^c\) | -0.4 ± 1.3              | -0.3 ± 1.5                  | 0.4 ± 1.9                 | <0.01       |
| Healthy weight score (%)\(^a,b,c\) |                  |                            |                          | <0.01       |
| Poor                     | 16.0                     | 35.2                       | 61.7                     |            |
| Intermediate             | 32.0                     | 31.0                       | 34.0                     |            |
| Ideal                    | 52.0                     | 33.8                       | 43.0                     |            |
| LS7 Health Score with Device Weight Score\(^a,b,c\) | 7.8 ± 0.8               | 7.0 ± 1.4                  | 5.8 ± 0.6                | <0.01       |

|                          | Resilient (\( n = 77 \)) | Concordant (\( n = 164 \)) | Uncoupled (\( n = 51 \)) | \( P \) value |
|--------------------------|--------------------------|-----------------------------|--------------------------|-------------|
| Moderate exercise (min/week)\(^a\) | 99.6 ± 116.6             | 158.6 ± 188.1               | 120.4 ± 174.9            | <0.04       |
| Difference between self-reported and digital device measured (min) | 102.1 ± 202.6           | 66.4 ± 254.0                | 54.3 ± 219.4             | 0.45        |
| Vigorous exercise (min/week) | 160.3 ± 187.2            | 199.5 ± 284.4               | 133.5 ± 153.8            | 0.18        |
| Difference between self-reported and digital device measured (min) | -77.9 ± 179.9           | -97.0 ± 282.1               | -97.9 ± 156.0            | 0.83        |
| Physical activity score (%) |                        |                            |                          | 0.56        |
| Poor                     | 0.0                      | 0.0                        | 0.0                      |            |
| Intermediate             | 37.7                     | 36.0                       | 47.1                     |            |
| Ideal                    | 62.3                     | 64.0                       | 52.9                     |            |
| LS7 health score with device activity score\(^a,b,c\) | 7.8 ± 0.9               | 7.0 ± 1.4                  | 5.8 ± 0.7                | <0.01       |

|                          | Resilient (\( n = 84 \)) | Concordant (\( n = 171 \)) | Uncoupled (\( n = 52 \)) | \( P \) value |
|--------------------------|--------------------------|-----------------------------|--------------------------|-------------|
| LS7 Health score with both weight and activity score\(^a,b\) | 7.7 ± 0.9               | 7.0 ± 1.5                  | 5.9 ± 0.7                | <0.01       |

**Categorical variables are analyzed by Chi-Square test. Continuous variables are analyzed by ANOVA. Post-hoc comparisons were done by Bonferroni correction. Non-parametric variables were analyzed by Kruskal–Wallis test. Post-hoc comparisons were done by Dunn’s test.**

\(^a\) \( P < 0.05 \) Resilient versus Concordant  
\(^b\) \( P < 0.05 \) Resilient versus Uncoupled  
\(^c\) \( P < 0.05 \) Concordant versus Uncoupled
resulted in a similar distribution of participants with intermediate and ideal activity scores among the phenogroups. Participants in the three phenogroups also recorded a similar number of daily steps, suggesting that contact time with their digital health devices was similar between the groups.

**Discussion**

In the current study, we used digital health device recorded sleep data and the validated American Heart Association's Life Simple 7 survey tool to identify sleep-ideal cardiovascular health phenogroups. Using American Academy of Sleep Medicine guidelines to define adequate and non-adequate sleep, we found that participants segregated into one of three phenogroups: resilient, uncoupled, or concordant. The resilient, uncoupled, and concordant phenogroups are based on having ideal cardiovascular health, but non-adequate sleep; non-ideal cardiovascular health and adequate sleep; or matched cardiovascular health and sleep status, respectively. When examining differences between these phenogroups, we found that individuals belonging to the resilient phenogroup were younger and had a lower prevalence of diabetes mellitus, hypertension, and hypercholesterolemia than the other groups while participants in the uncoupled group had a high burden of cardiovascular risk factors. There were also significant differences between the phenogroups with respect to modifiable health behaviors, such as diet and exercise. When digital device recorded weight was examined, differences between the phenogroups persisted. Interestingly, digital device recorded exercise data revealed that individuals in the concordant and uncoupled groups performed more minutes per week of vigorous exercise than they reported. Taken together, these findings demonstrate that acquiring digital health device recorded sleep duration is not only feasible in studies of ideal cardiovascular health but is likely to be more reliable than survey data. Furthermore, digital health device recorded sleep duration should be included in these types of studies as it revealed that the relationship between sleep duration and ideal cardiovascular health is more complex than previously reported.

Although prior studies have examined the relationship between ideal cardiovascular health and sleep duration, these studies relied on self-reported sleep duration and did not identify or describe the resilient, concordant, and uncoupled phenogroups. One large study of 7784 individuals without cardiovascular disease who participated in the NHANES study reported that participants with very short (<6 h) or very long (≥9 h) sleep duration had decreased odds of ideal cardiovascular health. Among study participants, only 21.3% had ideal cardiovascular health defined as having an ideal score for a minimum of five of seven cardiovascular health factors and behaviors evaluated by the Life's Simple 7 survey [19]. In contrast to the NHANES study, our study measured sleep duration via digital health device, included participants with prevalent cardiovascular disease, and defined ideal cardiovascular health by the calculated Life's Simple 7 Health Score [11, 22]. Furthermore, we found that only a subgroup of individuals who had short or very long sleep duration had non-ideal cardiovascular health scores. Another study that examined the relationship between self-reported sleep habits and ideal cardiovascular health in women reported that adequate sleep duration and higher quality sleep were associated with ideal scores in at least four of seven Life's Simple 7 cardiovascular health factors and behaviors categories [18]. Although we were not able to assess sleep quality, we also found that participants that recorded adequate sleep duration were more likely to have ideal scores in five or more Life's Simple 7 categories.

The relationship between sleep duration and cardiovascular health is complex and sleep may be a surrogate marker for other health factors and behaviors that have adverse cardiovascular effects. A report from the United Kingdom Biobank project found that individuals who self-reported long (non-adequate) duration sleep had higher relative odds of tobacco use, lower levels of physical activity, obesity, and poor diet [25]. Other studies have reported that non-adequate sleep was associated with a higher odds ratio of impaired fasting glucose levels, diabetes mellitus, hypertension, or hypercholesterolemia [26, 27]. The importance of these relationships is demonstrated by the finding that higher levels of coronary artery calcification and higher brachial-ankle pulse wave velocity, a marker of arterial stiffness, associated with very short and very long sleep duration in a cohort of individuals without established cardiovascular disease [28]. Longitudinal studies have also reported that participants with non-adequate sleep, particularly short sleep duration, were more likely to have cardiovascular events than individuals with adequate sleep duration [29].

There are several limitations to our study that may influence generalizability of the findings. First, we enrolled a relatively small sample size and some of our participants had prevalent cardiovascular disease. Our study design was direct-to-participant and we used transmitted digital health device measured data to assess sleep duration [30]. There has been some controversy regarding the accuracy of digital health devices for recording sleep duration and stages. Several studies have
evaluated the performance of digital health devices that record sleep using polysomnography and reported heterogeneous results with digital health devices overestimating, showing no difference, or underestimating standard actigraphy results. These studies, however, differed in the populations enrolled and the devices studied (reviewed in [31]), suggesting that further clinical studies are required. There are limitations related to wearable sleep trackers, including inherent differences between commercial devices, understanding device outcomes, the effects of device position on performance, and device reliability as these monitors rely on post-processed heart rate signals (reviewed in [31]). Furthermore, in our study, full sleep staging was only available in a subset of participants as some participants devices recorded in the classic as opposed to the stage mode. Since we did not administer a sleep questionnaire, we were also unable to assess sleep quality and we were unable to compare self-reported with digital health device measured sleep duration. Nonetheless, activity tracker data has been compared with patient-reported sleep outcomes and been shown to classify health status accurately in patients with heart disease [32]. Finally, we do not have longitudinal outcome data to determine if the phenogroups that we identified in our study cohort are associated with increased risk for, or protection from, cardiovascular events.

Conclusions
In summary, our study demonstrates the utility of digital health device measured sleep duration within the context of a direct-to-participant study design for assessing the association between sleep duration and ideal cardiovascular health. Furthermore, we identified three distinct sleep-cardiovascular health phenogroups, which underscores the necessity of incorporating sleep assessments into studies of cardiovascular health and disease. These phenogroups revealed that the association between sleep duration and ideal cardiovascular health is complex and that subgroups exist where sleep duration and ideal cardiovascular health are discordant. The relationship between these phenogroups and cardiovascular outcomes should be investigated in future studies as they may have implications for therapeutic interventions to improve cardiovascular morbidity and mortality.

Abbreviations
NHANES: National Health and Nutrition Examination Survey; REM: Rapid eye movement.

Acknowledgements
Not applicable.

Authors’ contributions
Conceptualization, J.A.L. and E.M.A; formal analysis, J.A.L.; investigation, J.A.L. and E.M.A; data curation, J.A.L.; writing—original draft preparation, J.A.L. and E.M.A; writing—review and editing, J.A.L. and E.M.A. All authors have read and agreed to the published version of the manuscript.

Funding
This research was funded by the American Heart Association AIM 19A1ML34980000, the National Institutes of Health/National Heart, Lung, and Blood Institute U01 HL125215 (J.A.L.).

Availability of data and materials
For information regarding data availability, please contact the corresponding author. The data are not publicly available due to privacy restrictions and protection of personal data.

Declarations

Ethics approval and consent to participate
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Advarra Institutional Review Board (approval #31995, approved 11/10/2016). Informed consent was obtained from all subjects involved in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests related to this work. The funders participated in the design of the study. The funders had no role in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Author details
1 Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, NRB0630K, Boston, MA 02215, USA.
2 Division of Cardiovascular Medicine, Brigham and Women's Hospital, 350 Longwood Ave., Boston, MA 02215, USA.

Received: 27 May 2021 Accepted: 22 September 2021
Published online: 14 October 2021

References
1. Liu Y, Wheaton AG, Chapman DP, Cunningham TJ, Lu H, Croft JB. Prevalence of healthy sleep duration among adults—United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(6):137–41.
2. Watson NF, Horn E, Duncan GE, Buchwald D, Vitiello MV, Turk Kheimer E. Sleep duration and area-level deprivation in twins. Sleep. 2016;39(1):67–77.
3. Yin J, Jin X, Shan Z, Li S, Huang H, Li P, et al. Relationship of sleep duration with all-cause mortality and cardiovascular events: a systematic review and dose-response meta-analysis of prospective cohort studies. J Am Heart Assoc. 2017;6(9):e005947.
4. Covassin N, Singh P. Sleep duration and cardiovascular disease risk: epidemiologic and experimental evidence. Sleep Med Clin. 2016;11(1):81–9.
5. Aggarwal S, Loomba RS, Arora RR, Molnar J. Associations between sleep duration and prevalence of cardiovascular events. Clin Cardiol. 2015;38(11):671–6.
6. Liu Y, Wheaton AG, Chapman DP, Croft JB. Sleep duration and chronic diseases among U.S. adults age 45 years and older: evidence from the 2010 Behavioral Risk Factor Surveillance System. Sleep. 2013;36(10):1421–7.
7. Sabanayagam C, Shankar A. Sleep duration and cardiovascular disease: results from the National Health Interview Survey. Sleep. 2010;33(8):1037–42.
8. Merikanto I, Lahti T, Puijoki J, Vanhala M, Peltonen M, Laatikainen T, et al. Associations of chronotype and sleep with cardiovascular diseases and type 2 diabetes. Chronobiol Int. 2013;30(4):470–7.
9. Fang J, Wheaton AG, Keenan NL, Greenland KJ, Perry GS, Croft JB. Association of sleep duration and hypertension among US adults varies by age and sex. J Am Heart Assoc. 2012;25(3):335–41.
10. Gangwisch JE, Feskanich D, Malaspina D, Shen S, Forman JP. Sleep duration and risk for hypertension in women: results from the nurses’ health study. Am J Hypertens. 2013;26(7):903–11.

11. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D; Appel LJ, Van Horn L, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586–613.

12. Sanchez E. Life’s simple 7: vital but not easy. J Am Heart Assoc. 2018;7(11):e009324.

13. Ensorro DM, Vasan RS, Xanthakis V. Twenty-year trends in the American Heart Association Cardiovascular Health Score and impact on subclinical and clinical cardiovascular disease: the Framingham offspring study. J Am Heart Assoc. 2018;7(11):e008741.

14. Corlin L, Short MI, Vasan RS, Xanthakis V. Association of the duration of ideal cardiovascular health through adulthood with cardiometabolic outcomes and mortality in the Framingham offspring study. JAMA Cardiol. 2020;5(5):549–56.

15. Nguyen ATH, Saeed A, Bams CE, Swanson J, Emechebe N, Mansuri F, et al. Usefulness of the American Heart Association’s ideal cardiovascular health measure to predict long-term major adverse cardiovascular events (From the Heart SCORE Study). Am J Cardiol. 2021;138:20–5.

16. Ramirez-Velez R, Saavedra JM, Lobelo F, Celis-Morales CA, Pozo-Cruz BD, Garcia-Hermosa A. Ideal cardiovascular health and incident cardiovascular disease among adults: a systematic review and meta-analysis. Mayo Clin Proc. 2018;93(11):1589–99.

17. Ommerborn MJ, Blackshear CT, Hickson DA, Griswold ME, Kwatra J, Djousse L, et al. Ideal cardiovascular health and incident cardiovascular events: the Jackson heart study. Am J Prev Med. 2016;51(4):502–6.

18. Makarem N, St-Onge MP, Liao M, Lloyd-Jones DM, Aggarwal B. Association of sleep characteristics with cardiovascular health among women and differences by race/ethnicity and menopausal status: findings from the American Heart Association Go Red for Women Strategically Focused Research Network. Sleep Health. 2019;5(5):501–8.

19. Cash RE, Beverly Hery CM, Panchal AR, Bower JK. Association between sleep duration and ideal cardiovascular health among US adults, national health and nutrition examination survey, 2013–2016. Prev Chronic Dis. 2020;17:E43.

20. Leopold JA, Davis RB, Antman EM. Data from digital health devices informs ideal cardiovascular health. J Personal Med. 2021;11(3):189.

21. Haghayegh S, Khoshnevis S, Smolensky MH, Diller KR, Castiotta RJ. Accuracy of wristband fitbit models in assessing sleep: systematic review and meta-analysis. J Med Internet Res. 2019;21(11):e16273.

22. Angell SY, McConnell MV, Anderson CAM, Bibbins-Domingo K, Boyle DS, Capewell S, et al. The American Heart Association 2030 impact goal: a presidential advisory from the American Heart Association. Circulation. 2020;141(9):e120–38.

23. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e39–596.

24. Centers for Disease Control and Prevention. Sleep and sleep disorders: Data and Statistics cdc.gov2017 [https://www.cdc.gov/].

25. Patterson F, Malone SK, Grandner MA, Lozano A, Perkett M, Hanlon A. Interactive effects of sleep duration and morning/evening preference on cardiovascular risk factors. Eur J Public Health. 2018;28(1):155–61.

26. Kim CR, Song YM, Shin JY, Gim W. Association between sleep duration and impaired fasting glucose in Korean adults: results from the Korean National Health and Nutrition Examination Survey 2011–2012. Korean J Fam Med. 2016;37(1):51–6.

27. Reis C, Dias S, Rodrigues AM, Sousa RD, Gregorio MJ, Branco J, et al. Sleep duration, lifestyles and chronic diseases: a cross-sectional population-based study. Sleep Sci. 2018;11(4):217–30.

28. Kim CW, Chang Y, Zhao D, Caiagos-Achirica M, Ryu S, Jung HS, et al. Sleep Duration, Sleep quality, and markers of subclinical arterial disease in healthy men and women. Arterioscler Thromb Vasc Biol. 2015;35(10):2238–45.

29. Kobayashi D, Kuniyama N, Osugi Y, Arita H, Takahashi O. Longitudinal relationships between cardiovascular events, risk factors, and time-dependent sleep duration. Cardiol J. 2018;25(2):229–35.

30. Cummings SR. Clinical trials without clinical sites. JAMA Intern Med. 2021;181(5):680–84.

31. de Zambotti M, Cellini N, Goldstone A, Colrain IM, Baker FC. Wearable sleep technology in clinical and research settings. Med Sci Sports Exerc. 2019;51(7):1538–57.

32. Meng Y, Speier W, Shufelt C, Joun S, Van Eyk JE, Bairiyi Merz CN, et al. A machine learning approach to classifying self-reported health status in a cohort of patients with heart disease using activity tracker data. IEEE J Biomed Health Inform. 2020;24(3):878–84.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.